 |
10 Companies | 11 Products |
|
|
11 Products | |
67 Diseases | |
197 Trials |  |
6615 News |  |
| «12...7891011121314151617...2627» |
- || aspirin / Generic mfg., dabigatran etexilate / Generic mfg.
Clinical, Journal: Dabigatran vs. Aspirin for Secondary Prevention After Embolic Stroke of Undetermined Source - Japanese Subanalysis of the RE-SPECT ESUS Randomized Controlled Trial. (Pubmed Central) - Dec 16, 2021
Dabigatran was putatively associated with a lower relative risk of recurrent stroke compared with aspirin in Japanese ESUS patients.
- || bivalirudin / Generic mfg.
Clinical, Review, Journal: A Review of Bivalirudin for Pediatric and Adult Mechanical Circulatory Support. (Pubmed Central) - Dec 16, 2021
A literature search identified ten studies in which bivalirudin was used in extracorporeal membrane oxygenation and five studies in which it was used in ventricular assist devices. The purpose of this review was to summarize the currently available literature for bivalirudin use for mechanical circulatory support in both adult and pediatric patients.
- || Clinical, Review, Journal: Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence. (Pubmed Central) - Dec 16, 2021
Recent randomized clinical trials suggest a role for DOACs in the treatment of VTED in patients with cancer. This review will discuss the existing evidence and future perspectives on the role of DOACs in the treatment of VTE based on the current evidence about their overall efficacy and safety and the limited information in patients with cancer; in addition, we will briefly review their pharmacokinetic properties with special reference to potential interactions.
- || aspirin / Generic mfg., dabigatran etexilate / Generic mfg.
Clinical, Journal: Dabigatran or Aspirin After Embolic Stroke of Undetermined Source in Patients With Patent Foramen Ovale: Results From RE-SPECT ESUS. (Pubmed Central) - Dec 16, 2021
P3
Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02239120.
- || dabigatran etexilate / Generic mfg.
Clinical, Journal: Pitfalls in the assessment of disseminated intravascular coagulation in patients on dabigatran. (Pubmed Central) - Dec 16, 2021
Like the routine coagulation assays, there is a dabigatran concentration dependent effect on the accuracy of fibrinogen and D-dimer assays. Falsely low fibrinogen results due to dabigatran may confound the assessment of DIC and diagnostic laboratories need to evaluate the performance of their own reagents.
- | paracetamol / Generic mfg.
Journal: Factor XIII cross-links fibrin(ogen) independent of fibrin polymerization in experimental acute liver injury. (Pubmed Central) - Dec 16, 2021
The objective of this study was to determine the mechanisms of fibrin polymerization and cross-linking in acute liver injury induced by acetaminophen (APAP) overdose...In biochemical assays, peroxynitrite inhibited thrombin-mediated fibrin polymerization in a concentration-dependent manner without affecting fibrin(ogen) cross-linking over time. These studies depict a unique pathology wherein thrombin-catalyzed fibrin polymerization is circumvented to allow tissue deposition and FXIII-dependent fibrin(ogen) cross-linking.
- || aspirin / Generic mfg., dabigatran etexilate / Generic mfg.
Clinical, Journal: Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis. (Pubmed Central) - Dec 16, 2021
P3
Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02239120.
- | Journal: Impaired Fibrinolysis in the Antiphospholipid Syndrome. (Pubmed Central) - Dec 16, 2021
This review aims to summarize the present knowledge of the mechanisms involved in impaired fibrinolysis in APS patients. We also present a case from clinical practice as an illustration of fibrinolysis impairment in APS patients from a real-life setting.
- || Clinical, Journal: International multi-centre, multi-platform study to validate Taipan snake venom time as a lupus anticoagulant screening test with ecarin time as the confirmatory test: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. (Pubmed Central) - Dec 16, 2021
We also present a case from clinical practice as an illustration of fibrinolysis impairment in APS patients from a real-life setting. TSVT/ET are validated for LA detection in non-anticoagulated patients and those on VKAs or DFXaIs.
- | Journal: Venous puncture wound hemostasis results in a vaulted thrombus structured by locally nucleated platelet aggregates. (Pubmed Central) - Dec 16, 2021
Furthermore, early steps in thrombus assembly were sensitive to P2Y inhibition and late steps to thrombin inhibition. Based on these results, we propose a Cap and Build, puncture wound paradigm that should have translational implications for bleeding control and hemostasis.
- | Journal: Synthesis and evaluation of peptidic thrombin inhibitors bearing acid-stable sulfotyrosine analogues. (Pubmed Central) - Dec 16, 2021
In order to overcome the inherent instability of the native modification, we report the synthesis of two sulfonate analogues and their incorporation into two thrombin-inhibiting sulfopeptides. The effective mimicry of these sulfonate analogues for native sulfotyrosine was validated in the context of their thrombin inhibitory activity and binding mode, as determined by X-ray crystallography.
- || Clinical, Review, Journal: Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. (Pubmed Central) - Dec 16, 2021
However, FXI is emerging as a potential safer target for new anticoagulants because FXI plays a greater part in thrombosis than in hemostasis. In this paper, we (a) explain the rationale for considering anticoagulation therapy in patients with kidney failure to reduce atherothrombotic events, (b) highlight the limitations of current anticoagulants in this patient population, (c) explain the potential benefits of FXI inhibitors, and (d) summarize ongoing studies investigating FXI inhibition in patients with kidney failure on dialysis.
- | Journal: Identification of a substrate-like cleavage-resistant thrombin inhibitor from the saliva of the flea Xenopsylla cheopis. (Pubmed Central) - Dec 16, 2021
The crystal structure of XC-43 in complex with thrombin shows that despite its substrate-like binding mode, XC-43 is not detectably cleaved by thrombin and that it interacts with the thrombin surface from the enzyme catalytic site through the fibrinogen-binding exosite I. The low rate of hydrolysis was verified in solution experiments with XC-43 which show the substrate to be largely intact after two hours of incubation with thrombin at 37° C. The low rate of XC-43 cleavage by thrombin may be attributable to specific changes in the catalytic triad observable in the crystal structure of the complex or to extensive interactions in the prime sites that may stabilize the binding of cleavage products. Based on the increased arterial occlusion time, tail bleeding time, and blood coagulation parameters in rat models of thrombosis XC-43 could be valuable as an anticoagulant.
- | Preclinical, Journal: Based on Multi-Activity Integrated Strategy to Screening, Characterization and Quantification of Bioactive Compounds from Red Wine. (Pubmed Central) - Dec 16, 2021
Finally, 77 active components from red wine were screened and 12 ingredients out of them were selected for quantification based on the integration of multi-activity. Collectively, the multi-activity integrated strategy was helpful for the rapid and effective discovery of bioactive components, which provided reference for exploring the health care function of food.
- || Clinical, Journal: Factor Xa Inhibitors for Patients after Mechanical Heart Valve Replacement? (Pubmed Central) - Dec 13, 2021
Finally, DOACs seem to represent a feasible treatment option in patients with mechanical heart valves, but further studies are needed to evaluate clinical safety. In addition to the ongoing PROACT Xa trial with apixaban in patients after aortic On-X valve implantation, studies in an all-comer collective with rivaroxaban could be promising.
- |||| Review: DOACs interfere with PT/PTT/TT! ⬆️PT Xa inhibitors RivaroXaban>EdoXaban>ApiXaban ⬆️PTT DabigaTran>Xa inhib ⬆️TT DabigaTran = Direct Thrombin Inhibitor PT/PTT mixing studies incomplete correction in presence of DOAC Short review on subject from #ASH21 https://t.co/vREFOrywrZ (Twitter) - Dec 13, 2021
- The Anticoagulant Properties of Protamine: New Mechanistic Insights into Its Interaction with Factor V (GWCC - Hall B5, Level 1) - Dec 4, 2021 - Abstract #ASH2021ASH_6992;
These effects were not mimicked using some other basic molecules . This study provides new insights into the molecular mechanism for the adverse anticoagulant effects of protamine and advances the development of alternative UFH antidotes free from intrinsic anticoagulant properties.
- | bivalirudin / Generic mfg.
Retrospective data, Journal: Efficacy and Safety of Bivalirudin During Percutaneous Coronary Intervention in Chronic Total Occlusion: A Retrospective Study. (Pubmed Central) - Nov 29, 2021
(Clin Ther. 2021;43:XXX-XXX)
- | Journal: Short tail stories: the hirudin-like factors HLF6 and HLF7 of the Asian medicinal leech, Hirudinaria manillensis. (Pubmed Central) - Nov 29, 2021
In contrast, some synthetic variants effectively inhibit thrombin, even with tails as short as six amino acid residues in length. Our data indicate that size and composition of the C-terminal tail of hirudins and HLFs can vary in a great extent, yet the full protein may still retain the ability to inhibit thrombin.
- || Review, Journal: Anticoagulants for acute ischaemic stroke. (Pubmed Central) - Nov 29, 2021
Treatment with anticoagulants reduced recurrent stroke, deep vein thrombosis, and pulmonary embolism but increased bleeding risk. Data do not support the routine use of any of the currently available anticoagulants for acute ischaemic stroke.
- | Journal: Hirudin, a thrombin inhibitor, attenuates TGF-β-induced fibrosis in renal proximal tubular epithelial cells by inhibition of protease-activated receptor 1 expression via S1P/S1PR2/S1PR3 signaling. (Pubmed Central) - Nov 25, 2021
In conclusion, hirudin attenuated TGF-β-induced fibrosis in proximal renal tubular epithelial HK-2 cells by inhibiting PAR1 expression via the S1P/S1PR2/S1PR3 signaling pathway. Therefore, hirudin may be considered as a promising therapeutic agent for RIF.
- rivaroxaban / Generic mfg., aspirin / Generic mfg.
A Case of Recurrent Bilateral Central Retinal Vein Occlusion in an Otherwise Healthy Adolescent Male () - Nov 24, 2021 - Abstract #ASH2021ASH_6904;
Perhaps, there is a familial component predisposing recurrent thrombosis in this patient. Whole exome sequencing is pending to evaluate for a genetic predisposition to his findings.
- enoxaparin sodium / Generic mfg.
Thromboembolic Complications in a Pediatric Patient Population: Treatment with Direct Oral Anticoagulants. Monitoring of Treatment Efficiency with D-Dimer Levels and Safety Profile By Thromboelastogram () - Nov 24, 2021 - Abstract #ASH2021ASH_6336;
Familiarity with their use in the general pediatric population with thrombosis secondary to inflammatory disorders and rheumatologic disease is currently not as prevalent due to the widespread more conventional anticoagulation practice with the fractionated heparins in particular Lovenox...In conclusion, DOAC are a safe and effective alternative to LMW Heparin in pediatric patients with arterial or venous thrombosis. Monitoring should include determination of D-Dimer levels for efficacy of treatment and TEG in cases with arterial disease where bleeding may be a secondary complication of therapy.
- | dabigatran etexilate / Generic mfg.
Journal: Increased mucosal thrombin is associated with Crohn's disease and causes inflammatory damage through Protease-Activated Receptors activation. (Pubmed Central) - Nov 21, 2021
Our data demonstrated that increased local thrombin activity, as it occurs in the colon of patients with inflammatory bowel disease, causes mucosal damage and inflammation. Colonic thrombin and protease-activated receptor-1 appear as possible mechanisms involved in mucosal damage and loss of function and therefore represent potential therapeutic targets for treating inflammatory bowel disease.
- | cisplatin / Generic mfg., dabigatran etexilate / Generic mfg.
Journal: Dabigatran mitigates cisplatin-mediated nephrotoxicity through down regulation of thrombin pathway. (Pubmed Central) - Nov 21, 2021
However, pretreatment of animals with either low or high doses of Dab significantly improved kidney function and decreased oxidative stress and apoptotic markers. We conclude that thrombin is an important factor in the pathogenesis of CDDP kidney toxicity via activation of ERK1/2, P53 and caspase-3 pathway, which can be effectively blocked by Dab.
- || Review, Journal: G-quadruplex-based aptamers targeting human thrombin: Discovery, chemical modifications and antithrombotic effects. (Pubmed Central) - Nov 17, 2021
Considering the growing need of new efficient anticoagulant agents associated with the strong therapeutic potential of these thrombin inhibitors, the research on thrombin binding aptamers is still a very hot and intriguing field. Herein, we comprehensively described the state-of-the-art knowledge on the DNA-based aptamers targeting thrombin, especially focusing on the optimized analogues obtained by chemically modifying the oligonucleotide backbone, and their biological performances in therapeutic applications.
- | Journal: Fibrinolytic and Thrombolytic Effects of an Enzyme Purified from the Fruiting Bodies of Boletus pseudocalopus (Agaricomycetes) from Korea. (Pubmed Central) - Nov 17, 2021
It could also delay activated partial thromboplastin time and prothrombin time. These results suggest that the enzyme may have characteristics of a trypsin or serine-like enzyme with fibrinolytic and thrombolytic activities and may have potential as an antithrombotic agent for blood clotting disorders.
- ||| Integrilin (eptifibatide) / Takeda, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, P3 data, Journal: The multiarm optimization of stroke thrombolysis phase 3 acute stroke randomized clinical trial: Rationale and methods. (Pubmed Central) - Nov 16, 2021
These results suggest that the enzyme may have characteristics of a trypsin or serine-like enzyme with fibrinolytic and thrombolytic activities and may have potential as an antithrombotic agent for blood clotting disorders. Multiarm optimization of stroke thrombolysis is an innovative and collaborative project that is the culmination of many years of dedicated efforts to improve outcomes for stroke patients.
- | Preclinical, Journal: Dialdehyde pectin-crosslinked and hirudin-loaded decellularized porcine pericardium with improved matrix stability, enhanced anti-calcification and anticoagulant for bioprosthetic heart valves. (Pubmed Central) - Nov 16, 2021
In vivo results revealed that the AP + Hirudin-PP specimens recruited the minimum immune cells in the implantation experiment, and also presented an excellent anti-calcification effect. Overall, AP + Hirudin-PP was endowed with competitive collagen stability (compared with GA-fixed PP), excellent hemocompatibility, good HUVECs-cytocompatibility, low immunogenicity and outstanding anti-calcification, suggesting that AP + Hirudin-PP might be a promising alternative to GA-fixed PP and exhibited a bright prospect in the clinical applications of BHVs.
- || argatroban / Generic mfg.
Clinical, Journal: Use of Argatroban in Donor Lung Procurement: A Case Report. (Pubmed Central) - Nov 12, 2021
CONCLUSIONS The ultimate success of grafts without thromboembolic complications suggests the use of argatroban in multiorgan procurement in the setting of a HIT-positive recipient is safe and effective. This case report highlights an alternative to the traditional process of organ procurement with heparin, in which patients at risk of coagulopathies secondary to HIT are able to receive organs when traditional protocols would otherwise be prohibitive.
- | Journal: Tailoring the effect of antithrombin-targeting therapy in haemophilia A using in silico thrombin generation. (Pubmed Central) - Nov 10, 2021
However, the variation in response to AT reduction was large between patients, indicating that this approach should be tailored to each individual patients. Ideally, TG and thrombin dynamics simulation could in the future contribute to the management of patients undergoing AT targeting therapy.
- bivalirudin / Generic mfg.
[VIRTUAL] RETROSPECTIVE EVALUATION OF BIVALIRUDIN DOSING IN PATIENTS WITH RENAL IMPAIRMENT () - Nov 9, 2021 - Abstract #ACFORUM2021ACFORUM_1;
Ideally, TG and thrombin dynamics simulation could in the future contribute to the management of patients undergoing AT targeting therapy. Based on the results of this study, bivalirudin starting doses should be based on renal function, and institutional guidelines should be optimized to achieve timely therapeutic DTI levels in patients with renal dysfunction.
- || Clinical, Journal: The use of direct oral anticoagulants in patients with ventricular assist devices: is there hope for Factor Xa inhibition? (Pubmed Central) - Nov 7, 2021
We identified eight pertinent studies, including a single randomised controlled trial and seven case reports/series. Limited numbers and significant study heterogeneity limits interpretation, however Factor Xa inhibitors appear to be feasible alternatives, favourable to direct thrombin inhibitors, although further research is required.
- | Journal: Immediate high-dose intravenous immunoglobulins followed by direct thrombin-inhibitor treatment is crucial for survival in Sars-Covid-19-adenoviral vector vaccine-induced immune thrombotic thrombocytopenia VITT with cerebral sinus venous and portal vein thrombosis. (Pubmed Central) - Nov 7, 2021
Limited numbers and significant study heterogeneity limits interpretation, however Factor Xa inhibitors appear to be feasible alternatives, favourable to direct thrombin inhibitors, although further research is required. No abstract available
- Structure-Activity Relationship Analysis of Analogs of Rhosin, a RhoA Inhibitor, Reveals a New Generation of Improved Antiplatelet Agents (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_5694;
In summary, evaluation of Rhosin/R-G04 analogs in a platelet activity screen identified a new generation of improved small-molecule RhoA inhibitors, including an enantiomer with significantly improved efficacy. These analog studies of novel anti-platelet agents provide a new approach to effectively and reversibly manipulate platelet activities.
- bivalirudin / Generic mfg.
Use of Bivalirudin-Specific Monitoring Assays in Ventricular Assist Device Patients (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_4907;
The two experimental assays had excellent correlation with each other and good correlation with the c-dTT; however, the fact that the c-dTT results shifted dramatically with a clinical laboratory platform change is illustrative of the need for a bivalirudin-specific monitoring assay as an essential tool for improving outcomes at our center and across centers. More research is needed to understand which type of monitoring assay (dTT or anti-FIIa) may be better suited to particular clinical circumstances.
- rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Analysis of Inter-Observer Agreement of Adjudication of Colors of Pad Colors of Doac Dipstick to Determine Presence or Absence of Direct Oral Anticoagulants in Outpatients’ Urine Samples (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_4883;
Given the encouraging results, the ongoing study should allow the device’s validation as an accurate, easy-to-use assessment tool for determination of the presence or absence of DOACs in patients’ urine samples also based on a very low inter-observer variability. The aforementioned data confirm the results of the first interim analysis presented in the ISTH 2021 congress.
- The Anticoagulant Properties of Protamine: New Mechanistic Insights into Its Interaction with Factor V (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_4847;
These effects were not mimicked using some other basic molecules . This study provides new insights into the molecular mechanism for the adverse anticoagulant effects of protamine and advances the development of alternative UFH antidotes free from intrinsic anticoagulant properties.
- Chronically Elevated Interleukin-6 Disturbs the Coagulation Cascade in Mice (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_3669;
These findings show the role of chronically elevated IL-6 in driving the accumulation of A2m on the surface of erythrocytes, thereby mediating a phenotype of increased bleeding complications. This work was supported by the DFG KA4035/1-1 and by the German Ministry for Education and Research (BMBF 01EO1503)
- USP Standardized Mixtures of Bovine, Ovine and Porcine Heparin Exhibit Comparable Biologic Effects to Referenced Single Sourced Heparins and May be Interchangeable, (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_2617;
These studies support the hypothesis that a blended heparin product from bovine, ovine, and porcine tissue, when standardized in USP unit-equivalent proportions, exhibits a comparable anticoagulant profile to the single species heparins. These findings suggest that there is a potential for development of blended heparin to stabilize supply chain of this important anticoagulant and warrant clinical validation.
- Neutrophil Extracellular Traps (NETs) Contribute to the Formation of Microvascular Thrombosis in Immune Thrombotic Thrombocytopenic Purpura (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_2566;
These results demonstrate for the first time NETosis and NETs formation are common in patients with acute iTTP and in Adamts13 -/- mice after being stimulated with shigatoxin; DNase I appears to be highly efficacious eliminating the NETs and platelet/neutrophil-dominant thrombosis under arterial flow. Our findings support the pathogenetic role of NETs in the onset and progression of iTTP, and the therapeutic potential of DNase I in such a fatal disease.
- Thrombin-Induced Oxidative Phosphorylation in Platelets Is Repressed By Dengue Virus through Inhibition of the PI3K/Akt Signaling Pathway (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_2552;
Dengue virus inhibits thrombin-induced phosphorylation at different levels in the platelet. First, by reducing the expression of the GPIb molecule on the platelet surface.
- dabigatran etexilate / Generic mfg., ibrutinib / Generic mfg.
Investigating the Roles of Platelet PAR4 in Hemostasis, Thrombosis and Viral Infection Using a Newly Generated PAR4 Floxed Mouse (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_2545;
Our results in mice demonstrate that 1) platelet PAR4 is not required for initial hemostatic plug formation but is necessary for maintaining hemostatic plug stability, 2) loss of platelet PAR4 protects from arterial thrombosis, and 3) platelet PAR4 does not alter the course of H1N1 IAV infection, at least at the virus dose used in this study. In summary, we generated a novel mouse line carrying a floxed PAR4 allele which can be used to investigate cell-specific roles of PAR4 in disease.
- Resolving Interference of Direct Oral Anticoagulants (DOACs) on Routine Coagulation, Thrombophilia, and Lupus Anticoagulant Testing Using Activated Carbon (GWCC - B405-B407, Level 4) - Nov 5, 2021 - Abstract #ASH2021ASH_2340;
The DOAC-Remove had no effect on test results obtained in the plasma from untreated patients and from patients on traditional anticoagulants. It effectively removed all 3 tested DOACs from the plasma of treated patients, allowing an accurate measurement of routine and esoteric coagulation tests in DOAC treated patients without withholding the treatment.
- || Zontivity (vorapaxar) / Merck (MSD)
Review, Journal: Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar. (Pubmed Central) - Nov 2, 2021
Based upon further subgroup analysis of both the TRA 2°P-TIMI 50 trial and TRACER trial, Vorapaxar was found to be potentially beneficial in patients with peripheral artery disease, coronary artery bypass grafting, and ischemic stroke. There are current trials in progress that are further evaluating the use of Vorapaxar in those conditions, and future research and trials are necessary to fully determine the utility of this drug.
- ||| fondaparinux / Generic mfg., argatroban / Generic mfg.
Clinical, Journal, Adverse events: Bleeding and Thrombotic Adverse Events in Hospitalized Patients Under Empiric Treatment for Suspected Heparin-Induced Thrombocytopenia While Awaiting Confirmatory Testing. (Pubmed Central) - Oct 30, 2021
There was no difference in AE based on time to initiation of empiric treatment and no advantage to reduced dosing with either anticoagulant. These findings challenge assumptions surrounding empiric HIT management.
- | Savaysa (edoxaban) / Daiichi Sankyo, Fraxiparine (nadroparin) / Aspen
Journal: Performance Characteristics of DOAC Dipstick in Determining Direct Oral Anticoagulants in Urine. (Pubmed Central) - Oct 28, 2021
The factor Xa and thrombin inhibitor pads did not interact with heparin, nadroparin, fondaparinux, or coumadin...In conclusion, we have demonstrated that interobserver variability when interpreting the DOAC Dipstick test strip is low and that factor Xa and thrombin inhibitor pads do not react to other anticoagulants such as heparins and coumadin. R-Hirudin and argatroban can be detected by the thrombin inhibitor pad and abnormal urine colors can be detected by the urine color pad to prevent false interpretation of the results in patient urine samples.
- || dabigatran etexilate / Generic mfg.
Clinical, Journal: A comprehensive appraisal of dabigatran etexilate clinical evidence and applications: a 10-year-long story. (Pubmed Central) - Oct 27, 2021
More recently, the availability of idarucizumab, a specific reversal agent, has increased the safety of dabigatran use in clinical practice, especially for those patients with severe and life-threatening bleeding. This review aims to summarize current evidence on dabigatran, starting from its pharmacological characteristics, and providing an updated overview of pivotal randomized controlled trials and real-world data on its efficacy and safety.
- || Ichorcumab (JNJ-64179375) / J&J
PK/PD data, Journal: Translational PK/PD and model-informed development of JNJ-67842125, a F reversal agent for JNJ-64179375, a long-acting thrombin inhibitor. (Pubmed Central) - Oct 27, 2021
This review aims to summarize current evidence on dabigatran, starting from its pharmacological characteristics, and providing an updated overview of pivotal randomized controlled trials and real-world data on its efficacy and safety. The results enabled selection of JNJ-67842125 as the RA for JNJ-9375.
- || dabigatran etexilate / Generic mfg., warfarin / Generic mfg.
Clinical, Journal: Post-thrombotic Syndrome in Patients with Venous Thromboembolism Treated with Dabigatran or Warfarin: a Long-term Cross-sectional Follow-up of RE-COVER Study Patients. (Pubmed Central) - Oct 27, 2021
The results enabled selection of JNJ-67842125 as the RA for JNJ-9375. In this long-term cross-sectional study, the prevalence of PTS, recurrent VTE, and HRQoL were similar in patients treated with dabigatran and warfarin.